• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    Cellceutix Corporation (CTIX)

    -Other OTC
    2.56 Down 0.02(0.78%) Jul 2, 3:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Cellceutix Corporation
    100 Cumming Center
    Suite 151-B
    Beverly, MA 01915
    United States - Map
    Phone: 978-236-8717
    Fax: 978-921-6564
    Website: http://www.cellceutix.com

    Index Membership:N/A
    Full Time Employees:9

    Business Summary 

    Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compounds include Kevetrin, an anti-cancer compound that is in Phase I clinical trial for the treatment of cancer; Prurisol, an anti-psoriasis drug candidate that has completed Phase I clinical trial; and Brilacidin, an antibiotic candidate for the treatment of diabetic foot ulcer infections, and other indications, such as ophthalmic and otitic infections, as well as for other skin infections and oral mucositis. The company’s preclinical stage compounds comprise KM 391 for the treatment of autism; KM 277 for the treatment of rheumatoid arthritis; KM 278 for the treatment of arthritis/asthma; KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency, as well as Delparantag, a synthetic small-molecule for the treatment of other diseases, including chronic obstructive pulmonary disease. In addition, its other product candidates include compounds active against other gram-negative bacterias, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cellceutix Corporation

    Key Executives 
    Mr. Leo Ehrlich CPA, 57
    Chairman, Chief Exec. & Financial Officer, Principal Accounting Officer and Sec.
    Dr. Krishna Menon Ph.D., VMD, MRCS, 67
    Pres, Chief Scientific Officer and Director
    Dr. W. James Alexander M.D., MPH, FACP, 65
    Chief Operations Officer
    Dr. Daniel Jorgensen M.D., MPH, MBA,
    Chief Medical Officer
    Dr. Daniel M. Jorgensen M.D.,
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders